Clinical trials: Dose Administration Aids
Respiratory Tract Infections, HIV Infections
Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO)
Single-arm, single-center, Phase I/II clinical trial, in four groups. Individuals with HIV infection taking Efavirenz (EFV) and two nucleoside reverse transcriptase inhibitors (NRTI) who have undetectable (Groups 1 and 2) or…
- Trial name
- IMPAACT4TB (NCT03435146)
- Testing
- 3HP plus DTG +2NRTIs
- Where
- South Africa
- Volunteers
- 135 people
- Sponsor
- The Aurum Institute NPC
HIV Infections
BMS-Reyataz Study in Treatment in Naive Subjects to Compare the Efficacy and Safety Between Boosted Reyataz and Kaletra When in Combination With Fixed Dose Truvada
The purpose of this study is to evaluate the safety, tolerability and antiviral effects of atazanavir (ATV) plus ritonavir (RTV) versus a combination drug of lopinavir (LPV) plus RTV.
- Trial name
- NCT00272779
- Testing
- ATV, RTV, Tenofovi-Emtricitabine (TDF/FTC) tablet
- Where
- 79 sites in United States, Argentina and 27 more
- Volunteers
- 1,057 people
- Sponsor
- Bristol-Myers Squibb
Acquired Immune Deficiency Syndrome, Human Immunodeficiency Virus
Dose Optimisation of Stavudine for the Treatment of HIV Infection
The purpose of this study is to demonstrate whether low dose stavudine (d4T) is non-inferior (in terms of both viral suppression and toxicity) to tenofovir (TDF) after 2 years of HIV treatment.
- Trial name
- D4T (NCT02670772)
- Testing
- Stavudine, Tenofovir Disoproxil Fumarate
- Where
- 3 sites in India, South Africa and 1 more
- Volunteers
- 1,077 people, healthy volunteers welcome
- Sponsor
- Willem Daniel Francois Venter
HIV Infections
Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV
A single dose of nevirapine (SD NVP) given to an HIV infected pregnant woman followed by a single dose to her infant has been shown to be an effective way of reducing the risk of mother-to-child transmission (MTCT) of HIV.
- Trial name
- P1060 (NCT00307151)
- Testing
- Lamivudine, Lopinavir/ritonavir, Nevirapine
- Where
- 10 sites in India, Malawi and 5 more
- Volunteers
- 452 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
HIV Infections
A Phase IIIB Open-Label, Comparative Study to Evaluate Saquinavir Soft Gel Capsule (SGC) Treatment in Combination With Other Antiretrovirals in HIV-1 Infected Antiretroviral-Naive Patients
To determine the proportion of patients whose plasma HIV-1 RNA level falls below the level of detection (< 400 copies/ml) at week 16 and 24 of study therapy.
- Trial name
- NCT00002178
- Testing
- Ritonavir, Nelfinavir mesylate, Saquinavir
- Where
- 2 sites in United States
- Volunteers
- 375 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Safety and Effectiveness of Combining Hydroxyurea (HU) With Didanosine (ddI) and Stavudine (d4T) for Treatment of HIV-Infected Adults
The purpose of this study is to compare the safety and effectiveness of 9 doses of HU in order to find the best dose of HU to use with ddI and d4T in fighting HIV infection.
- Trial name
- NCT00002427
- Testing
- Hydroxyurea, Stavudine, Didanosine
- Where
- 18 sites in United States
- Volunteers
- 225 people
- Sponsor
- Research Institute for Genetic and Human Therapy
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of arsenic trioxide in treating patients who have advanced…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003395
- Testing
- arsenic trioxide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
HIV Infections
BOOST: Study of Increased Dosage of Lopinavir/Ritonavir (LPV/r)
This study will look to see if increasing the standard dose of Kaletra is tolerated and if it will lower viral loads to undetectable levels.
- Trial name
- NCT00414284
- Testing
- Increased dose of Kaletra
- Where
- United States
- Sponsor
- Community Research Initiative of New England
HIV/AIDS, Tuberculosis, Pulmonary
INSTI's For The Management of HIV-associated TB
This study is being conducted to assess the antiretroviral activity of a fixed-drug, single tablet, combination of Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir alafenamide 25mg (Biktarvy®) dosed twice daily in HIV-1 infected…
- Trial name
- INSIGHT (NCT04734652)
- Testing
- Biktarvy®, TLD- fixed-drug combination single tablet
- Where
- South Africa
- Volunteers
- 122 people
- Sponsor
- Centre for the AIDS Programme of Research in South Africa
HIV Infections
Safety and Effectiveness of a New Protease Inhibitor, BMS-232632, in HIV-Positive Patients Who Have Received Previous Treatment
The purpose of this study is to look at the safety and effectiveness of an experimental protease inhibitor (a type of anti-HIV drug) called BMS-232632.
- Trial name
- NCT00004584
- Testing
- Atazanavir, Ritonavir, Saquinavir
- Where
- 38 sites in United States, Canada and 3 more
- Sponsor
- Bristol-Myers Squibb
HIV Infections
VENICE Study Nevirapine Full Dose/Dose Escalation
This study aims to compare the trough plasma concentrations of nevirapine after 7 days of treatment at the full dose from baseline with dose escalation in patients taking efavirenz who switch to nevirapine due to neuropsychiatric…
- Trial name
- VENICE (NCT00704249)
- Testing
- nevirapine
- Where
- 15 sites in Spain
- Volunteers
- 80 people
- Sponsor
- Clinical Trial Agency of HIV Study Group
Tuberculosis
Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
Primary Objective: To evaluate the effect of single and repeated administration of rifapentine given as daily or weekly regimen on steady-state pharmacokinetic parameters of efavirenz, emtricitabine and tenofovir given as a fixed…
- Trial name
- NCT01690403
- Testing
- rifapentine (M000473), EFZ EMT TDF
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sanofi
HIV Infections
A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs
The purpose of this study is to compare the safety and effectiveness of 2 dosing schedules (once daily vs twice daily) of lamivudine (3TC) given with stavudine (d4T) and either indinavir (IDV) or nelfinavir (NFV) for 24 weeks.
- Trial name
- NCT00002442
- Testing
- Indinavir sulfate, Nelfinavir mesylate, Lamivudine
- Where
- 12 sites in United States
- Sponsor
- Glaxo Wellcome
HIV Infections
Safety and Activity of the Oral HIV Entry Inhibitor AMD11070 in HIV Infected Patients
New treatment options are critical for treatment-experienced HIV infected patients with drug resistance. HIV entry inhibitors have been shown effective in patients with resistance to other anti-HIV drugs.
- Trial name
- NCT00089466
- Testing
- AMD11070
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
AIDS
A Drug Safety and Dose-exploratory Clinical Study of Azvudine Tablets in Patients Who Have Not Received Anti-HIV Treatment
The primary objective of this trial was to evaluate the safety and preliminary evaluation of Azvudine tablets (FNC) in combination with reverse transcriptase inhibitors therapy in treatment-naive patients with HIV infection.; the…
- Trial name
- FNC (NCT04109183)
- Testing
- The subjects were randomized to the treatment group of 3TC or different doses of FNC. The background drugs were EFV and TDF.
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
HIV Infections
Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection
The purpose of this study is to evaluate the safety of the experimental drug Bay 50-4798 in HIV positive patients receiving HAART and to test the drug's effect on the CD4+ T-cell count.
- Trial name
- NCT00059462
- Testing
- Interleukin-2 SA, HAART
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Acquired Immunodeficiency Syndrome, HIV Infections
Open-Label Pilot Study to Evaluate Switching From a Regimen Consisting of Raltegravir Plus Emtricitabine/Tenofovir DF Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients
This study will evaluate the efficacy of Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF)) single-tablet regimen (STR) after switching from a regimen consisting of raltegravir plus…
- Trial name
- NCT01533259
- Testing
- Stribild
- Where
- 9 sites in United States
- Volunteers
- 48 people
- Sponsor
- Gilead Sciences
Pneumonia, Pneumocystis Carinii, HIV Infections
Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection
Primary: To compare the toxicity of daily versus weekly dapsone in HIV-infected infants and children; to study the pharmacokinetics of orally administered dapsone in HIV-infected infants and children.
- Trial name
- NCT00000739
- Testing
- Dapsone
- Where
- 46 sites in United States, Puerto Rico
- Volunteers
- 96 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Safety of and Immune Response to an HIV Vaccine (VRC-HIVDNA009-00-VP) Administered With Interleukin-2/Immunoglobulin (IL-2/Ig) DNA Adjuvant in Uninfected Adults
This study will test the safety of and immune system response to a new HIV vaccine. The vaccine in this study is made from HIV DNA produced in a laboratory.
- Trial name
- NCT00069030
- Testing
- VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP
- Where
- 7 sites in United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
Therapeutic Drug Monitoring and Viral Resistance Testing in the Treatment of HIV-Infected Children
This study will evaluate a new treatment strategy called therapeutic drug monitoring (TDM) in HIV-infected children and adolescents.
- Trial name
- NCT00032669
- Testing
- HAART
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)